> top > docs > PubMed:32082518 > annotations

PubMed:32082518 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-73 Sentence denotes Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis:
T2 74-134 Sentence denotes A Randomized Placebo-Controlled Double-Blind Clinical Trial.
T3 135-270 Sentence denotes BACKGROUND Inflammatory bowel diseases are managed by different methods, which may not be well tolerated because of their side effects.
T4 271-369 Sentence denotes Recently, pro-prebiotics are considered as a supplementary treatment in gastrointestinal diseases.
T5 370-512 Sentence denotes In this study, the effect of Lactocare® (ZistTakhmir Company) was investigated on the disease severity in mild to moderate ulcerative colitis.
T6 513-702 Sentence denotes METHODS In this randomized, double-blind clinical trial (Iranian Registry of Clinical Trials number: IRCT201407271264N5), 60 patients with mild to moderate ulcerative colitis were included.
T7 703-810 Sentence denotes An 8-week trial was carried out comparing Lactocare® as a supplement with standard therapy against placebo.
T8 811-901 Sentence denotes Simple Clinical Colitis Activity Index (SCCAI) was measured at baseline and after 8 weeks.
T9 902-1055 Sentence denotes Statistical analysis was performed using paired ttest to assess the temporal changes (before and after the treatment) in the mean of SCCAI in each group.
T10 1056-1111 Sentence denotes Chi-square test was used to compare the response rates.
T11 1112-1247 Sentence denotes Odds ratios (OR) and the 95% confidence intervals (95%CI) were also calculated. p values of less than 0.05 were considered significant.
T12 1248-1383 Sentence denotes RESULTS A significant decreased mean SCCAI was seen in the intervention group (4.56 ± 2.56) vs. placebo group (6.54 ± 2.47) (p < 0.05).
T13 1384-1487 Sentence denotes Response to treatment was seen in 64.3% of the treatment group vs. 47% in the placebo group (p = 0.18).
T14 1488-1642 Sentence denotes Response to treatment was observed in 90.9% of patients with ulcerative colitis for more than 5 years compared with 44.4% of the control group (p = 0.01).
T15 1643-1892 Sentence denotes CONCLUSION Regarding the effectiveness of pre-probiotics in mitigating symptoms in patients with ulcerative colitis, it could be suggested to try pre-probiotics in the standard treatment particularly in those with more than five years ofthe disease.
T1 0-73 Sentence denotes Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis:
T2 74-134 Sentence denotes A Randomized Placebo-Controlled Double-Blind Clinical Trial.
T3 135-270 Sentence denotes BACKGROUND Inflammatory bowel diseases are managed by different methods, which may not be well tolerated because of their side effects.
T4 271-369 Sentence denotes Recently, pro-prebiotics are considered as a supplementary treatment in gastrointestinal diseases.
T5 370-512 Sentence denotes In this study, the effect of Lactocare® (ZistTakhmir Company) was investigated on the disease severity in mild to moderate ulcerative colitis.
T6 513-702 Sentence denotes METHODS In this randomized, double-blind clinical trial (Iranian Registry of Clinical Trials number: IRCT201407271264N5), 60 patients with mild to moderate ulcerative colitis were included.
T7 703-810 Sentence denotes An 8-week trial was carried out comparing Lactocare® as a supplement with standard therapy against placebo.
T8 811-901 Sentence denotes Simple Clinical Colitis Activity Index (SCCAI) was measured at baseline and after 8 weeks.
T9 902-1055 Sentence denotes Statistical analysis was performed using paired ttest to assess the temporal changes (before and after the treatment) in the mean of SCCAI in each group.
T10 1056-1111 Sentence denotes Chi-square test was used to compare the response rates.
T11 1112-1247 Sentence denotes Odds ratios (OR) and the 95% confidence intervals (95%CI) were also calculated. p values of less than 0.05 were considered significant.
T12 1248-1383 Sentence denotes RESULTS A significant decreased mean SCCAI was seen in the intervention group (4.56 ± 2.56) vs. placebo group (6.54 ± 2.47) (p < 0.05).
T13 1384-1487 Sentence denotes Response to treatment was seen in 64.3% of the treatment group vs. 47% in the placebo group (p = 0.18).
T14 1488-1642 Sentence denotes Response to treatment was observed in 90.9% of patients with ulcerative colitis for more than 5 years compared with 44.4% of the control group (p = 0.01).
T15 1643-1892 Sentence denotes CONCLUSION Regarding the effectiveness of pre-probiotics in mitigating symptoms in patients with ulcerative colitis, it could be suggested to try pre-probiotics in the standard treatment particularly in those with more than five years ofthe disease.